STIM · Neuronetics, Inc.
$3.30
+0.27 (+8.91%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Should the lender call the facility, the Company is not projected to have the liquidity required to meet its requirement to pay off the loan. Therefore, substantial doubt exists about the Company's ability to continue as a going concern. Actions within the Company's control to meet its minimum revenue covenant include improvements to its revenue cycle management, introducing new treatment options at its clinic locations and pursuing new strategies within its NeuroStar business to accelerate sales growth and optimize its product mix. The Company's ability to meet its liquidity needs, including meeting future revenue and liquidity covenants, is dependent on growth in existing and acquired product and service lines and the realization of synergies related to its acquisition of Greenbrook. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period.”View the 10-Q filed Aug 11, 2026
Market Cap
$251.45M
Shares
76.20M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.30
Open$3.06
Day$2.95–3.31
52W close$1.18–3.69
Avg vol 30d3.1M
Short int9.3M · 12.2% float · 3.4d
Short vol14%
Last earningsAug 11, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 14, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+99%
above
Price vs 50-day avg
+88%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+104%
trailing
6-month return
+166%
trailing
YTD return
+139%
this year
Relative strength
+152%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +17 funds added
Insider flow
Accumulating
Net +$179.3K over 90 days · 0% sells
Short interest
Falling
12.24% of float · ▼ -0.5% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 3-yr range
Squeeze score
99
high risk · 0–100
Fundamentals
Revenue growth
+31%
Y/Y
Gross margin
137%
expanding
EPS growth
+57%
Y/Y
Balance sheet
$50.8M
net debt
Quant / Vol
risk profile
Volatility
117%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
full year 2026
Total revenue
Initiated
$160M – $164M
prior FY $149.16M
midpoint +8.6% Y/Y
Gross margin
Initiated
48% – 50%
FY 2026
Operating Expenses
Non-GAAP
Initiated
$91M – $96M
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2025
Revenue
· first quarter 2026
$33M – $35M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+99%
Bullish
Price vs 50-day avg
+88%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +17 funds added
Insider flow
Accumulating
Net +$179.3K over 90 days · 0% sells
Short interest
Falling
12.24% of float · ▼ -0.5% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $3 · 84%
Range high $4
vs 200-day avg +99%
vs 50-day avg +88%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $254K | Three Months Ended June 30, 2026 | — |
| Gross margin | 51.1% | three months ended June 30, 2026 filing | — |
| Growth in Patients Treated with TMS | 23% | 2025 | — |
| Growth in Spravato Revenue | 57% | 2025 | — |
| NeuroStar TMS Customers | 92 | as of August 2026 | — |
| Treatments Administered | 9,133,855 | as of August 2026 | — |
| Unique Patients Treated | 253,412 | as of August 2026 | — |
| NeuroStar systems shipped | 34 | Q1 2026 | — |
|
|
|||
| operating cash flow | $0.9M | fourth quarter 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STIM
this stock
Neuronetics, Inc.
|
$251.45M | +139.1% | +30.5% | — | 12.2% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STIM | +38.7% | +103.7% | +166.1% | +66.7% | +139.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +38.3% | +99.3% | +152.4% | +62.8% | +125.3% |